燕 王

Dr. 燕 王


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2025 in ACS Omega
Verified
Journal Article
Open access
YMYi Mou
Yi Mou
YZYao Zhao
Yao Zhao
SWShuai Wen
Shuai Wen
XLXing Li
Xing Li
WZWenshuo Zhang
Wenshuo Zhang
燕王燕 王
燕 王
Imatinib mesylate has been identified as a tyrosine kinase inhibitor that selectively inhibits Abl tyrosine kinases, including Bcr-Abl. It exhibits many polymorphic forms, with the most stable and commercialized polymorphs known as the α and β forms. In the present study, the compatibility between the polymorphs of Imatinib mesylate and selected excipients (MCC, HPMC, PVPP, SiO2, MS, and CaHPO4) was investigated by differential scanning calorimetry (DSC), Raman spectra, X-ray diffraction (XRD) technique, and isothermal stress testing (IST). The results revealed that polymorph α of Imatinib mesylate has poor compatibility with selected excipients at high temperatures. As a contrary, polymorph β of Imatinib mesylate shows high compatibility with the selected excipients except MS under high temperatures.

14 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
燕王燕 王
燕 王
SWShuai Wen
Shuai Wen
YZYao Zhao
Yao Zhao
LGLijuan Gui
Lijuan Gui
YMYi Mou
Yi Mou
DWDongkai Wang
Dongkai Wang
Tofacitinib citrate (TOC) is clinically used primarily for the treatment of moderate to severe rheumatoid arthritis in patients who are intolerant or inadequately responsive to methotrexate. In this study, a new polymorph of TOC (form II) was prepared using solvent crystallization. The currently marketed form I and the self-prepared form II were characterized by XRD, DSC, FT-IR, and SEM, confirming that form II is a new polymorphic form of TOC. This new polymorph was then used in the development of TOC sustained-release tablets. In the formulation design, mannitol with low hygroscopicity was used to replace sorbitol. By adding a certain amount of microcrystalline cellulose to the tablet core and maintaining the mannitol content between 60 ~ 70% of the total core weight, an in vitro dissolution behavior similar to that of the reference formulation (f2 > 50) was achieved. This indicates that replacing sorbitol with mannitol as the osmotic agent in the osmotic pump tablet core is a practical and effective method. Additionally, key preparation processes for the TOC sustained-release tablets were investigated. The results suggest that the coating weight gain of the self-prepared sustained-release tablets should be controlled between 6% and 7%, and the suitable range for laser-drilled orifice diameter is 0.55 ~ 0.90 mm.

26 December 2025 in Nano
Verified
Journal Article
Closed access
HLHong-Wei Li
Hong-Wei Li
燕王燕 王
燕 王
JLJi Li
Ji Li
DWDongkai Wang
Dongkai Wang